• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Gevo Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    12/15/25 9:05:36 AM ET
    $GEVO
    Major Chemicals
    Industrials
    Get the next $GEVO alert in real time by email
    false --12-31 0001392380 0001392380 2025-12-09 2025-12-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): December 9, 2025

     

     

    Gevo, Inc.

    (Exact name of registrant as specified in its charter)

     

     

    Delaware 001-35073 87-0747704
    (State or other jurisdiction (Commission File Number) (IRS Employer
    of incorporation)   Identification No.)

     

    345 Inverness Drive South, Building C, Suite 310
    Englewood
    , CO 80112

    (Address of principal executive offices) (Zip Code)

     

    Registrant’s telephone number, including area code: (303) 858-8358

     

    N/A

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading symbol   Name of exchange on which registered
    Common Stock, par value $0.01 per share   GEVO   Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

    Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    On December 9, 2025, Patrick R. Gruber announced his intention to retire as Chief Executive Officer of Gevo, Inc., a Delaware corporation (the “Company”), effective on April 1, 2026 (the “Effective Date”), and in connection with Dr. Gruber’s retirement announcement, the Board of Directors of the Company (the “Board”) appointed Paul D. Bloom as the Company’s President, effective immediately, and as the Company’s Chief Executive Officer, effective as of the Effective Date. Dr. Gruber will continue as a member of Board following his retirement as Chief Executive Officer.

     

    In addition, in conjunction with Dr. Bloom’s appointment as President, the Board approved, effective immediately, (i) an increase in the size of the Board to ten directors, (ii) appointed Dr. Bloom as a Class III director with a current term that will expire at the annual meeting of stockholders to be held in 2028, (iii) appointed Dr. Gruber as the Executive Chair of the Board, and (iv) appointed William H. Baum as the lead independent director of the Board. The Board and Dr. Bloom also agreed to negotiate in good faith and finalize the terms of an amended employment agreement in connection with his new role as President and future position as Chief Executive Officer of the Company.

     

    Dr. Bloom, age 51, has served as the Chief Business Officer of the Company since February 2025, having previously served the Company as its Chief Carbon Officer and Chief Innovation Officer from September 2021 through February 2025, and as its Chief Technology Officer from March 2021 through September 2021. Prior to joining the Company, Dr. Bloom served as Vice President, Sustainable Materials for Archer-Daniels-Midland Company (“ADM”), a publicly-traded food processing and commodities trading company, from March 2020 until March 2021. From November 2013 through March 2020, Dr. Bloom served as Vice President, Process and Chemical Research at ADM, and prior to that, Dr. Bloom served in a series of commercial and technical roles of increasing responsibility at ADM between 2001 and 2013. Dr. Bloom holds an undergraduate degree from Illinois State University and a Ph.D. from Iowa State University.

     

    There are no arrangements or understandings between Dr. Bloom and any other persons pursuant to which he was appointed as an officer or director of the Company. There are no family relationships between Dr. Bloom and any of the Company’s directors, executive officers or persons nominated or chosen by the Company to become a director or executive officer. Dr. Bloom is not party to any related party transaction required to be reported pursuant to Item 404(a) of Regulation S-K.

     

    Item 5.03Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

     

    On December 9, 2025, the Board approved and adopted the Third Amended and Restated Bylaws of the Company (as amended and restated, the “Bylaws”), effective immediately. The amendments to the Bylaws were the result of a comprehensive review of the Bylaws and include certain provisions to modernize the Bylaws consistent with applicable law, including to:

     

    (i)modify the provisions for determining the presence of a quorum at all meetings of stockholders, to provide that the holders of one-third of the stock issued and outstanding and entitled to vote at the meeting, present in person (including by any means of remote communication authorized by the Board) or represented by proxy, shall constitute a quorum for all purposes, unless or except to the extent that the presence of a larger number may be required by law, the certificate of incorporation of the Company or the Bylaws;

     

    (ii)amend the voting standard for the approval of all matters at a stockholder meeting (other than the election of directors) to a “majority of the votes cast” standard;

     

    (iii)clarify the provisions around the list of stockholders made available before stockholder meetings, consistent with updates to Delaware law;

     

    (iv)incorporate and implement changes with respect to the “universal proxy” rules adopted by the Securities and Exchange Commission pursuant to Rule 14a-19 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”);

     

    (v)implement certain changes to terms and requirements of the advance notice provisions for business to be considered at annual meetings of stockholders of the Company, including the removal of advance notice provisions with respect to the removal of directors;

     

    (vi)amend provisions with respect to maintenance of books and records of the Company;

     

    (vii)clarify certain provisions related to (1) virtual meetings of stockholders and the Board, and (2) the use of electronic signatures; and

     

    (viii)make certain other updates and conforming, ministerial, or technical changes consistent with Delaware law.

     

     

     

     

    The foregoing description of the Bylaws is qualified in its entirety by reference to the Bylaws, which are attached hereto as Exhibit 3.1 and incorporated herein by reference.

     

    Item 7.01Regulation FD Disclosure.

     

    On December 15, 2025, the Company issued a press release announcing the retirement of Dr. Gruber and the promotion of Dr. Bloom. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

     

    The information in this Item 7.01 and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit
    No.
      Description
    3.1   Third Amended and Restated Bylaws of Gevo, Inc.
    99.1   Press Release of Gevo, Inc., dated December 15, 2025
    104   Cover Page Interactive Data File (Formatted as Inline XBRL)

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      GEVO, INC.
         
    Dated: December 15, 2025 By: /s/ E. Cabell Massey
        E. Cabell Massey
        Vice President, Legal and Corporate Secretary

     

     

     

    Get the next $GEVO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GEVO

    DatePrice TargetRatingAnalyst
    12/1/2025$3.00Outperform
    Northland Capital
    8/21/2023$2.00Market Perform
    Northland Capital
    12/14/2022$2.25Neutral
    UBS
    10/19/2022$2.29Hold
    Jefferies
    2/9/2022$5.00Buy
    Citigroup
    8/24/2021$10.00Buy
    Stifel
    More analyst ratings

    $GEVO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Gevo Names Paul Bloom as Incoming CEO to Succeed Long-Time Leader Patrick Gruber Who Will Retire on April 1, 2026

    ENGLEWOOD, Colo., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Gevo, Inc. (NASDAQ:GEVO), a leader in renewable fuel and chemicals, and carbon management, today announced a strategic leadership transition designed to position the company for continued growth and innovation. Effective December 9, 2025, Dr. Paul Bloom has been appointed President of Gevo, Inc. and a director on Gevo's Board of Directors. Gevo's long-standing Chief Executive Officer and board member, Dr. Patrick Gruber, has assumed the role of Executive Chair of the Board. Board Chairman William H. Baum has moved into the role of lead independent director. As part of the succession plan, Dr. Gruber will continue as Chief Executive Office

    12/15/25 9:00:00 AM ET
    $GEVO
    Major Chemicals
    Industrials

    Gevo Reports Third Quarter 2025 Financial Results

    ENGLEWOOD, Colo., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Gevo, Inc. (NASDAQ:GEVO) ("Gevo", the "Company", "we", "us" or "our"), a leading developer of cost-effective, renewable hydrocarbon fuels and chemicals that also can deliver significant carbon emission abatement, today announced financial results for the third quarter ended September 30, 2025. The Company reported a $3.7 million loss from operations and positive Adjusted EBITDA1 of approximately $6.7 million for the third quarter. This marks a second consecutive quarter of positive Adjusted EBITDA for the Company. Recent Corporate Highlights Consistent Performance: Gevo reported a $3.7 million loss from operations for the three months e

    11/10/25 4:01:00 PM ET
    $GEVO
    Major Chemicals
    Industrials

    Gevo North Dakota Sells Its Remaining 2025 45Z Production Tax Credits for $30 Million, Bringing the Contracted Total for the Year to $52 Million

    ENGLEWOOD, Colo., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Gevo, Inc. (NASDAQ:GEVO) announced the contracted sales of its remaining Section 45Z Clean Fuel Production Credits for 2025 from its Gevo North Dakota facility ("GevoND"), totaling $30 million, to Stifel Financial Corp. and Capital Community Bank, bringing the total sales for 2025 to $52 million, when combined with the previously announced $22 million worth of credits sold in July. These production tax credits were generated based on volumes of ethanol produced at GevoND and taking into account operating carbon sequestration and operating efficiencies. Gevo believes it is one of the first ethanol producer to sell Section 45Z credits direc

    11/5/25 9:00:00 AM ET
    $GEVO
    Major Chemicals
    Industrials

    $GEVO
    SEC Filings

    View All

    Gevo Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Gevo, Inc. (0001392380) (Filer)

    12/15/25 9:05:36 AM ET
    $GEVO
    Major Chemicals
    Industrials

    SEC Form 10-Q filed by Gevo Inc.

    10-Q - Gevo, Inc. (0001392380) (Filer)

    11/10/25 4:18:13 PM ET
    $GEVO
    Major Chemicals
    Industrials

    Gevo Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Gevo, Inc. (0001392380) (Filer)

    11/10/25 4:14:47 PM ET
    $GEVO
    Major Chemicals
    Industrials

    $GEVO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CFO Agiri Oluwagbemileke Yusuf exercised 68,404 shares at a strike of $1.18 and sold $169,183 worth of shares (73,284 units at $2.31), decreasing direct ownership by 2% to 271,224 units (SEC Form 4)

    4 - Gevo, Inc. (0001392380) (Issuer)

    12/8/25 4:39:08 PM ET
    $GEVO
    Major Chemicals
    Industrials

    VP Acctg and Treasurer Gendenjamts Davaajargal sold $5,943 worth of shares (2,560 units at $2.32), decreasing direct ownership by 4% to 60,217 units (SEC Form 4)

    4 - Gevo, Inc. (0001392380) (Issuer)

    12/5/25 5:35:04 PM ET
    $GEVO
    Major Chemicals
    Industrials

    Chief Cust Mkt & Brnd Officer Shafer Andrew sold $9,936 worth of shares (5,000 units at $1.99), decreasing direct ownership by 2% to 280,823 units (SEC Form 4)

    4 - Gevo, Inc. (0001392380) (Issuer)

    11/21/25 5:35:04 PM ET
    $GEVO
    Major Chemicals
    Industrials

    $GEVO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Northland Capital initiated coverage on Gevo with a new price target

    Northland Capital initiated coverage of Gevo with a rating of Outperform and set a new price target of $3.00

    12/1/25 9:35:34 AM ET
    $GEVO
    Major Chemicals
    Industrials

    Northland Capital initiated coverage on Gevo with a new price target

    Northland Capital initiated coverage of Gevo with a rating of Market Perform and set a new price target of $2.00

    8/21/23 9:21:52 AM ET
    $GEVO
    Major Chemicals
    Industrials

    UBS initiated coverage on Gevo with a new price target

    UBS initiated coverage of Gevo with a rating of Neutral and set a new price target of $2.25

    12/14/22 7:48:29 AM ET
    $GEVO
    Major Chemicals
    Industrials

    $GEVO
    Leadership Updates

    Live Leadership Updates

    View All

    Gevo Names Paul Bloom as Incoming CEO to Succeed Long-Time Leader Patrick Gruber Who Will Retire on April 1, 2026

    ENGLEWOOD, Colo., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Gevo, Inc. (NASDAQ:GEVO), a leader in renewable fuel and chemicals, and carbon management, today announced a strategic leadership transition designed to position the company for continued growth and innovation. Effective December 9, 2025, Dr. Paul Bloom has been appointed President of Gevo, Inc. and a director on Gevo's Board of Directors. Gevo's long-standing Chief Executive Officer and board member, Dr. Patrick Gruber, has assumed the role of Executive Chair of the Board. Board Chairman William H. Baum has moved into the role of lead independent director. As part of the succession plan, Dr. Gruber will continue as Chief Executive Office

    12/15/25 9:00:00 AM ET
    $GEVO
    Major Chemicals
    Industrials

    Gevo Appoints Industry Veteran James Barber, Ph.D. to Board of Directors

    ENGLEWOOD, Colo., May 27, 2025 (GLOBE NEWSWIRE) -- Gevo, Inc. (NASDAQ:GEVO), a leader in sustainable aviation fuel and renewable chemicals, announced today the appointment of James J. Barber, Ph.D., to its Board of Directors. Dr. Barber brings decades of executive leadership and board experience in public and private companies including fuels, chemicals, biobased materials, micro-optics, carbon nanofibers, joint ventures and licensing. Dr. Barber currently serves on the board of directors of Graham Corporation (NYSE:GHM), where he chairs the Compensation Committee and is a member of the Audit and Nomination and Governance Committees. Dr. Barber holds a Ph.D. in Organic Chemistry from the

    5/27/25 4:10:00 PM ET
    $GEVO
    $GHM
    Major Chemicals
    Industrials
    Industrial Machinery/Components

    Gevo Promotes Leke Agiri to Chief Financial Officer

    ENGLEWOOD, Colo., May 27, 2025 (GLOBE NEWSWIRE) -- Gevo, Inc. (NASDAQ:GEVO), is pleased to announce the appointment of Oluwagbemileke (Leke) Agiri as Chief Financial Officer, effective as of May 21, 2025. Mr. Agiri succeeds L. Lynn Smull, who will continue with the Company in a new role as Executive Vice President and Senior Advisor to the Chief Executive Officer, focusing on strategic initiatives and to aide and support a seamless transition. Mr. Agiri brings extensive experience and leadership in corporate finance, capital markets, and strategic growth, both organic and inorganic. Since joining Gevo in August 2022, he has served in key leadership roles, most recently as Executive Vice P

    5/27/25 4:01:00 PM ET
    $GEVO
    Major Chemicals
    Industrials

    $GEVO
    Financials

    Live finance-specific insights

    View All

    Gevo Reports Third Quarter 2025 Financial Results

    ENGLEWOOD, Colo., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Gevo, Inc. (NASDAQ:GEVO) ("Gevo", the "Company", "we", "us" or "our"), a leading developer of cost-effective, renewable hydrocarbon fuels and chemicals that also can deliver significant carbon emission abatement, today announced financial results for the third quarter ended September 30, 2025. The Company reported a $3.7 million loss from operations and positive Adjusted EBITDA1 of approximately $6.7 million for the third quarter. This marks a second consecutive quarter of positive Adjusted EBITDA for the Company. Recent Corporate Highlights Consistent Performance: Gevo reported a $3.7 million loss from operations for the three months e

    11/10/25 4:01:00 PM ET
    $GEVO
    Major Chemicals
    Industrials

    Gevo to Report Third Quarter 2025 Financial Results on November 10, 2025

    ENGLEWOOD, Colo., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Gevo, Inc. (NASDAQ:GEVO) announced today that it will host a conference call on November 10, 2025, at 4:30 p.m. ET (2:30 p.m. MT) to report its financial results for the third quarter that ended September 30, 2025. To participate in the live call, please register through the following event weblink: https://register-conf.media-server.com/register/BI33e4e5053f8644aa87e6a416132c4d8c After registering, participants will be provided with a dial-in number and pin. To listen to the conference call (audio only), please register through the following event weblink: https://edge.media-server.com/mmc/p/swydnbb2 A webcast replay will be availabl

    10/20/25 4:56:00 PM ET
    $GEVO
    Major Chemicals
    Industrials

    Gevo Reports Second Quarter 2025 Financial Results

    Achieves Positive Net Income in the Second Quarter and Positive Adjusted EBITDA1 for the Second Quarter and Six Months Ended June 30, 2025  Positive Net Income Attributable to Gevo of $2.1 million in the Second QuarterPositive Adjusted EBITDA1 of $17 million in the Second QuarterRevenues Increased $14 million Quarter-Over-QuarterPositive Earnings per Share Attributable to Gevo of $0.01 for the Second QuarterResults Driven by Successful Execution on Low-Carbon Ethanol and Carbon Capture Acquisition, First Sales of Clean Fuel Production Credits ENGLEWOOD, Colo., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Gevo, Inc. (NASDAQ:GEVO) ("Gevo", the "Company", "we", "us" or "our"), a leading develo

    8/11/25 4:01:00 PM ET
    $GEVO
    Major Chemicals
    Industrials

    $GEVO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Gevo Inc.

    SC 13G/A - Gevo, Inc. (0001392380) (Subject)

    11/12/24 4:02:11 PM ET
    $GEVO
    Major Chemicals
    Industrials

    Amendment: SEC Form SC 13G/A filed by Gevo Inc.

    SC 13G/A - Gevo, Inc. (0001392380) (Subject)

    11/4/24 11:58:10 AM ET
    $GEVO
    Major Chemicals
    Industrials

    Amendment: SEC Form SC 13G/A filed by Gevo Inc.

    SC 13G/A - Gevo, Inc. (0001392380) (Subject)

    7/8/24 4:32:39 PM ET
    $GEVO
    Major Chemicals
    Industrials